Global Paraneoplastic Syndrome Treatment Market Poised for Steady Expansion Global paraneoplastic syndrome treatment market is gaining strategic importance within the broader rare disease and oncology care landscape, driven by rising cancer prevalence and improved clinical recognition of autoimmune neurological disorders. Valued at USD 1.28 billion in 2024, the market is projected to grow from USD 1.37 billion in 2025 to USD 2.16 billion by 2031, registering a compound annual growth rate (CAGR) of 6.7% during the forecast period. This growth reflects increasing demand for early intervention, immunotherapy-driven treatment protocols, and multidisciplinary care models capable of managing complex paraneoplastic manifestations. Access the complete report https://www.24lifesciences.com/paraneoplastic-syndrome-treatment-market-9070

Mitochondrial Myopathy Diagnosis & Treatment Market to Reach USD 33.9 Million by 2032 Global mitochondrial myopathy diagnosis & treatment market is gaining measurable momentum as advances in genetic medicine, orphan drug development, and rare disease awareness reshape neuromuscular care. Valued at USD 22.6 million in 2024, the market is projected to grow from USD 23.9 million in 2025 to USD 33.9 million by 2032, registering a CAGR of 6.1% over the forecast period. This expansion reflects sustained investment in targeted therapies, improving diagnostic precision, and rising prioritization of lifelong care for pediatric-onset mitochondrial disorders. Access the market report https://www.24lifesciences.com/mitochondrial-myopathy-diagnosis-treatment-market-9538